Short answer
PTC THERAPEUTICS, INC. (PTCT) filed an 8-K current report with the SEC on October 29, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Q3 2026 financial results announced for quarter ended September 30, 2026.
PTC THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full results and management commentary available in Exhibit 99.1
- Investor focus: quarterly revenue, cash position, operating expenses and pipeline updates in the accompanying release
Item 7.01 · Regulation FD Disclosure
- Conference call scheduled for October 29, 2026 at 4:30 p.m. Eastern
- Management to review quarter ended September 30, 2026 financial results
- Updated corporate presentation signals additional corporate and pipeline updates for investors
- Presentation available through the company’s Investors Events and Presentations page
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $357.6M, up from $201.7M, led by Sephience product revenue of $181.9M
- Full-year 2026 revenue guidance raised to $1.29B-$1.32B, product revenue to $960M-$990M
- Sephience exceeded 2,000 active patients globally, with Q3 US revenue $145M and ex-US revenue $37M
- ST-920 acquired for $111M upfront, plus up to $100M in regulatory milestones, creating 2027 launch potential
- Net loss $51.7M, including $111M acquired in-process R&D, while cash and securities reached $2.13B
Item EX-99.2 · Exhibit EX-99.2
- 2026 product revenue guidance: $1.29-$1.32B, representing 64%-69% YoY growth
- Total revenue guidance: $960-$990M, with non-GAAP OpEx of $680-$720M
- Sephience generated $458M global revenue YTD through September 30, supporting launch-driven growth
- Cash balance $2.1B, with management targeting 2026 cash-flow breakeven
- ST-920 BLA submission for accelerated approval expected in Q4 2026, creating a near-term regulatory catalyst
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PTC THERAPEUTICS, INC. 8-K filings
Get the next PTCT 8-K as it lands
Follow PTCT for push alerts, or ask the research agent what this filing means.